Aims The aim of this study is to evaluate changes in cardiopulmonary exercise test (CPET) after percutaneous mitral valve repair (PMVR) with MitraClip in patients with heart failure with reduced ejection fraction who are potentially candidates for heart transplantation or destination left ventricular assist device. Methods and results Prospective registry of all consecutive patients with heart failure with reduced ejection fraction and functional mitral regurgitation (MR) underwent elective PMVR between October 2015 and March 2018 in our institution. Patients with preserved or mid-range left ventricular ejection fraction (>40%), advanced age (>75 years old), or severe co-morbidities (end-stage organ damage) were not included. Treadmill exercise testing with respiratory gas exchange analysis was carried out in 11 patients (male, 72.7%; median age, 67 years old) within the month prior to the procedure and at 6 month follow-up. PMVR was successfully performed in all patients. At 6 month follow-up, PMVR was associated with an improvement in New York Heart Association functional class (P = 0.021) and a reduction in MR severity (P = 0.013) and N-terminal pro-brain natriuretic peptide levels (2805 [1878-5022] vs. 1485 [654-3032] pg/mL; P = 0.012). All patients completed pre-procedural and post-procedural CPET, and all the studies showed a respiratory exchange ratio ≥1 and were consistent with sufficient exercise effort. Compared with pre-procedural CPET, patients showed a significant increase in exercise time (295 [110-335] vs. 405 [261-540] s; P = 0.047), VO 2 (9. 8 [9.1-13.4] vs. 13.5 [12.1-16.8] mL/kg/min; P = 0.033), ventilatory anaerobic threshold (510 [430-950] vs. 850 [670-1070] mL/kg/min; P = 0.033), peak O 2 pulse (7.2 [4.3-8.6] vs. 8.3 [6.2-11.8] mL/beat; P = 0.033), and workload (5 [3-6] vs. 6 [5-8] metabolic equivalents; P = 0.049). Conclusions Percutaneous mitral valve repair with MitraClip was associated with an enhancement in cardiopulmonary performance in patients with systolic heart failure and secondary MR.
Introduction
Percutaneous mitral valve repair (PMVR) with MitraClip has proven to effectively reduce mitral regurgitation (MR) and improve symptoms in patients at high risk for conventional surgery.
1 Cardiopulmonary exercise test (CPET) is a valuable key tool to evaluate functional capacity, determine prognosis, and guide therapies in patients with heart failure with reduced ejection fraction (HFrEF). 2, 3 To the best of our knowledge, no data are available regarding changes in CPET after PMVR.
S H O R T C O M M U N I C A T I O N

Aim
Our aim was to evaluate changes in CPET after PMVR in patients with HFrEF who are potentially candidates for heart transplantation or destination left ventricular assist device.
Methods
We conducted a prospective registry of all consecutive patients with functional MR (FMR) and HFrEF who underwent elective PMVR between October 2015 and March 2018 in our institution. Patients with preserved or mid-range left ventricular ejection fraction (LVEF > 40%), advanced age (>75 years old), or severe co-morbidities (end-stage organ damage) were not included. Patients with unimpaired preprocedural VO 2 > 18 mL/kg/min were excluded ( Figure 1 ). All patients underwent invasive angiogram before PMVR to exclude significant coronary artery disease, with two patients being revascularized within prior 90 days before clip implantation. Treadmill exercise testing with respiratory gas exchange analysis was carried out in 11 patients within the month prior to the procedure and at 6 month follow-up using a Schiller MTM-1500 ergometer (Polymed Chirurgical, Montreal, Canada). Current recommendations for CPET in this scenario were followed. 4 Wasserman's equation was used to estimate predicted VO 2 in each subject according to sex, predicted weight, and the use of treadmill test. 5 Patients breathed exclusively through a face mask and exhaled gases were analysed using sensors that allow breath-by-breath analysis with real-time plotting of the mean values. Respiratory exchange ratio (RER), defined as the ratio between carbon dioxide output and oxygen uptake, was estimated as a 10 to 60 s averaged value depending on the exercise protocol. A cut-off point ≥1.05 was set as an optimal exercise effort for maximal oxygen consumption (VO 2 ) estimation. In case of a RER between 1 and 1.05, the exercise was considered sufficient for peak VO 2 calculation if fulfilling one of the following criteria: achievement ventilatory anaerobic threshold, plateau in the VO 2 , maximal heart rate ≥90%, or perceived exertion with the Borg scale ≥8. CPETs with a RER below 1 were excluded. Clinical, echocardiographic, and laboratory features were also collected. Continuous variables were summarized as medians and interquartile range and compared using paired non-parametric Wilcoxon sign rank sum tests. Categorical variables were described as percentages and compared using paired McNemar test. A P-value of <0.05 was considered statistically significant.
Results
Baseline characteristics of included cohort are shown in Table  1 . All patients were at optimal medical therapy at maximum dose tolerated according to heart failure (HF) guidelines before PMVR: 100% were on beta-blockers, and all but two patients with severe chronic kidney disease were on inhibitors of the renin-angiotensin system. No significant changes in medical therapy were observed at 6 month follow-up ( Table  2) . PMVR was successfully performed in all patients. At 6 month follow-up, PMVR was associated with an improvement in New York Heart Association functional class and LVEF and a reduction in MR severity and N-terminal pro-brain natriuretic peptide ( Table 2 ). All patients completed preprocedural and post-procedural CPET, and all the studies Figure 1 Inclusion and exclusion criteria: flow chart for selection of patients. FMR, functional mitral regurgitation; GFR, glomerular filtrate rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; OMT, optimal medical therapy; PMVR, percutaneous mitral valve repair; VO 2 , maximal peak oxygen consumption.
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T. Benito-González et al. Cardiopulmonary stress test after MitraClip showed a RER ≥ 1 and were consistent with sufficient exercise effort. Compared with pre-procedural CPET, patients showed a significant increase in exercise time (P = 0.047), VO 2 (P = 0.033), ventilatory anaerobic threshold (P = 0.033), peak O 2 pulse (P = 0.033), and workload (P = 0.049) ( Table  2 and Figures 2-4 ).
Discussion
Some reports have already highlighted the effectiveness of PMVR in patients with advanced HF candidates for heart transplantation or left ventricular assist device. 6, 7 In our cohort, elective PMVR was related to an improved overall cardiopulmonary performance, including an increase in VO 2 as the most robust prognostic parameter of CPET. Some aspects should be pointed out regarding these findings. First, interpretation of pre-procedural and post-procedural CPETs results might be challenging, especially in patients with advanced age and severe co-morbidities.
3,8 Those patients
were not included in this study. Second, FMR is a common finding among patients with HFrEF and has a negative impact on exercise capacity and clinical outcomes on standalone medical therapy. 9 Third, from a physiopathological perspective, PMVR reduces MR, thus decreasing left-side volume overload and pulmonary pressures and increasing cardiac output. 10 And fourth, this haemodynamic enhancement has translated into positive left ventricular remodelling and improvement in clinical symptoms, quality of life, and 6 min walk test in different series. [11] [12] [13] Although only modest increments in LVEF have been reported in this scenario, these changes, alongside the reduction in regurgitant volume, imply an improvement in antegrade ejection flow that might be one of the underlying mechanisms for a better cardiopulmonary performance.
14 Given the good correlation reported between 6 min walk test and estimated VO 2 , 15 this result go alongside with prior findings. Because improvement in VO 2 has always been considered a relevant prognostic factor in patients with HFrEF, our observation may explain some of the benefits of the MitraClip therapy. At this regard, to date, larger randomized controlled trial addressing prognosis impact of PMVR Cardiopulmonary stress test after MitraClip 871 over medical therapy in patients with FMR showed a reduction in the need for advanced HF therapies, as well as an improved survival after clip implantation. 16 Conversely, the study of Obadia et al. 17 failed to show an improvement in prognosis after PMVR, which has been related to the inclusion of patients with very severely dilated left ventricular and less significant MR in this late study. Therefore, further trials are required to better discriminate best candidates for PMVR and determined if clinical improvement in patients with FMR translates in better survival outcomes and safe deference of advanced HF therapies.
Conclusions
In conclusion, although limited for the small number of patients included and the lack of a matched cohort, PMVR was related to an enhancement in cardiopulmonary performance in patients with systolic HF and no contraindication for advanced HF therapies in our series.
